Current Report Filing (8-k)
December 21 2017 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 15, 2017
XOMA CORPORATION
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
|
000-14710
|
|
Delaware
|
|
52-2154066
|
|
(Commission
File Number)
|
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
2200 Powell Street, Suite 310, Emeryville, California
|
|
94608
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code (510) 204-7200
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On December 15, 2017, XOMA Corporation (“XOMA”) appointed
Dee Datta, Ph.D., to serve as its Chief Business Officer. Dr. Datta joined XOMA from Forty Seven Inc. As the Vice President of Corporate Development at Forty Seven, Dr. Datta managed business development, strategy and transactions, company
financing, and investor relations. Dr. Datta joined Forty Seven from XOMA where she was the Senior Director of Business Development. During her time at XOMA, she successfully closed multiple transactions including licensing deals with large
pharmaceutical companies, such as Novartis and Novo Nordisk. Prior to joining the biotech industry in an operating role, Dr. Datta was a venture capitalist at The Column Group and Longitude Capital. As an investor, she has experience in
alternative financing strategies, such as royalty monetization, in addition to formation and management of portfolio companies. Dr. Datta started her career as the Founder and Vice President of a biotech startup, Allozyne, based on technologies
licensed from California Institute of Technology (Caltech). Dr. Datta received her Ph.D. from Caltech and MBA from Stanford University Graduate School of Business.
On December 20, 2017, XOMA appointed Danny Hart to serve as its Vice President, General Counsel. Mr. Hart joined XOMA from PDL
BioPharma, Inc. (“PDL”), where he most recently served as its Vice President, Business Development. While in his business development role at PDL, Mr. Hart led PDL’s royalty, debt and specialty pharma investment efforts.
Mr. Hart previously served in various legal capacities at PDL, most recently as its Deputy General Counsel and Assistant Secretary, where we led PDL’s transactional efforts in a legal capacity, completing over $1 billion in investment
transactions during his tenure at PDL. Mr. Hart began his legal career at the leading international law firms of Skadden, Arps and Hogan Lovells (fka Hogan & Hartson). Mr. Hart received his J.D. from Vanderbilt Law School and B.A.
from the University of Washington.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
XOMA CORPORATION
|
|
|
|
|
|
Date: December 21, 2017
|
|
|
|
/s/ James R. Neal
|
|
|
|
|
|
James R. Neal
|
|
|
|
|
|
Chief Executive Officer
|
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024
